Related Experiment Video
Updated: Aug 19, 2025

06:43
A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes
Published on: February 5, 2018
12.2K
CSPα in neurodegenerative diseases
1Department of Neurology, Renmin Hospital, Wuhan University, Wuhan, China.
Frontiers in Aging Neuroscience
|December 5, 2022
Summary
Adult-onset neuronal ceroid lipofuscinosis (ANCL) is linked to DNAJC5 gene mutations. This study investigates the CSPα protein
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Adult-onset neuronal ceroid lipofuscinosis (ANCL) is a rare neurodegenerative disorder.
- ANCL is characterized by epilepsy, cognitive decline, and motor dysfunction.
- Mutations in the DNAJC5 gene cause ANCL and are linked to other neurodegenerative diseases like Alzheimer's and Parkinson's.
Purpose of the Study:
- To investigate the functional properties of the cysteine string protein alpha (CSPα).
- To elucidate the pathogenic mechanisms underlying neurodegenerative diseases associated with CSPα.
Main Methods:
- Functional characterization of the CSPα protein.
- Exploration of molecular mechanisms in neurodegeneration.
Main Results:
- Detailed findings on CSPα protein function are presented.
- Insights into the role of CSPα in neurodegenerative disease pathogenesis are provided.
Conclusions:
- The study enhances understanding of CSPα's role in ANCL and other neurodegenerative conditions.
- Findings may contribute to developing therapeutic strategies for these diseases.
Related Concept Videos
Parkinson's Disease: Overview
650
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
650
Neural Regulation
39.7K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.7K
Alzheimer's Disease: Overview
612
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
612
Postsynaptic Potential (PSP)
3.1K
Postsynaptic potential (PSP) refers to a change in the electrical potential of a neuron when neurotransmitters released by presynaptic neurons bind to postsynaptic receptors. This potential can either be excitatory, leading to depolarization and ultimately action potential generation, or inhibitory, leading to hyperpolarization and suppression of the postsynaptic neuron.
There are two types of receptors: ionotropic and metabotropic.
The ionotropic receptor is the membrane protein that has an...
There are two types of receptors: ionotropic and metabotropic.
The ionotropic receptor is the membrane protein that has an...
3.1K
Alzheimer's Disease: Treatment
240
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
240
Glial Cells
88.1K
Overview
88.1K

